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Snnlm~fy 
Plasmodium vivax and the related monkey malaria, P. knowlesi, require interaction with the Duffy 
blood group antigen, a receptor for a family of chemokines that includes interleukin 8, to invade 
human erythrocytes. One P. v/vax and three P. lenowlesi proteins that serve as erythrocyte binding 
ligands in such interactions share sequence homology. Expression of different regions of the P v/vax 
protein in COS7 cells identified a cysteine-rich domain that bound Duffy blood group-positive 
but not Duffy blood group-negative human erythrocytes. The homologous domain of the P. know/esi 
proteins also bound erythrocytes, but had different specifidties. The P. v/vax and P. knowlesi binding 
domains lie in one of two regions of homology with the P. fakiparum sialic acid binding protein, 
another erythrocyte binding ligand, indicating conservation of the domain for erythrocyte binding 
in evolutionarily distant malaria species. The binding domains of these malaria ligands represent 
potential vaccine candidates and targets  for receptor-blockade  therapy. 
T 
he human malaria,  Plasmodium  vivax,  and the related 
monkey malaria, P. knowlesi, use the Duffy blood group 
antigen as a receptor to invade human erythrocytes  (1, 2). 
The Duffy blood group antigen has recently been shown to 
be a receptor for a family of chemokines that includes IL-8 
and melanoma growth-stimulating activity (MGSA) 1 (3). 
Duffy blood group-negative (Duffy negative) human erythro- 
cytes lack the Duffy blood group antigen and are refractory 
to invasion by P v/vax and P knowlesi. The invasion of erythro- 
cytes by malaria merozoites is a multi-step process that is medi- 
ated by several molecular interactions between the invading 
merozoite and the target erythrocyte. The binding of para- 
site ligands to the Duffy blood group antigen is required for 
the formation of an irreversible junction between P. knowlesi 
merozoites and Duffy-positive human erythrocytes and is fol- 
lowed by the entry of the merozoite into the erythrocyte (4). 
A  140-kD P. vivax protein and a 135-kD P. knowlesi protein, 
which bind Duffy-positive but not -negative human erythro- 
cytes, probably serve as ligands for  junction formation during 
invasion (5, 6). Affinity-purified Abs to the DS-kD P. knowlesi 
protein were used to clone the putative gene (or) encoding 
this protein from P. knowlesi (7). Two other related P. knowlesi 
genes (B and 3/) and the homologous P v/tax gene were cloned 
by cross-hybridization  to the P. knowlesi ot gene (8, 9). Inde- 
pendent of these studies, the gene encoding a sialic add binding 
protein of Pfakiparum, the other major human malaria, was 
t Abbreviations used in this paper: HSV gD, HSV glycoprotein  D; MGSA, 
mdanoma growth-stimulating  activity;  PDI, protein  disulfide  isomerase. 
also doned (10). These genes from P. knowlesi, R  v/vax, and 
Rfalcipatum have similar structures and share regions of amino 
acid sequence homology suggesting that they belong to a 
gene family encoding erythrocyte binding proteins (8). The 
extracellular domains of these proteins  can be divided into 
six regions based on amino acid sequence homology (8). Each 
protein has two cysteine-rich regions (regions II and VI, also 
referred to as the 5' and 3' cysteine-rich regions, respectively) 
which contain highly conserved cysteines and aromatic amino 
acid residues (8). In this paper, we identify one of these cysteine- 
rich regions (region II) as the binding domain of the P. v/vax 
and R  knowlesi  ligands.  The three R  knowlesi ligands  have 
different binding specificities that may provide redundancy 
in invasion pathways resulting in a survival advantage in case 
of mutations in host receptors. 
Materiah and Methods 
Construction of Recombinant Plasmids for Surface Expression in 
C087  Cells 
The plasmid pRE4 (provided by Drs. Gary Cohen and Rnselyn 
Eisenberg, University  of Pennsylvania,  Philadelphia,  PA), has been 
described previously  (11). It contains a SV40 origin of replication 
(SV40 or/), a Rous sarcoma virus LTR (RSV LTR) as a promoter 
and the SV40 early  polyadenylation  signal (SV40 polyA). The HSV 
glycoprotein  D gene (HSV  gD) was cloned in the HindIII cloning 
site downstream of the RSV LTR. HSV gD has a signal peptide 
of 25 amino acids at the NH2-terminal end and a 24 amino acid 
hydrophobic transmembrane stretch with a 30 amino acid cyto- 
plasmic tail at the COOH-terminal end (12). HSV gD has unique 
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acids downstream of the signal peptide cleavage site and the ApaI 
site is 71 amino adds upstream of  the COOH-terminal hydrophobic 
stretch. We have used the signal sequence and hydrophobic trans- 
membrane stretch of HSV gD to target different regions of the 
malarial erythrocyte  binding proteins to the surface of mammalian 
COS7 cells. The phsmid pRE4 was restricted with PvulI and ApaI 
to excise the central region of HSV gD encoding amino acids 33 
to 248. The restriction fragments were separated  by gel electropho- 
resis and the vector was recovered using Geneclean II (Stratagene, 
La Jolla, CA). DNA fragments encoding different regions of the 
P. vivax and P. knowlesi proteins were cloned in the vector using 
the PvulI and ApaI sites to make the following constructs: 
pHVDRll.  This construct contains DNA sequences  encoding 
region I (amino acids 27-214) of the P. vivax protein.  The PCK 
was used to amplify the DNA sequence encoding this region. The 
plasmid p192B which contains  the putative  gene encoding  the 
P. vivax Duffy antigen binding protein, was used as a template, and 
the primers, 5'TCT CGT CAG CTG GAT GCA GAA GGA CAT 
GACY and 5'ACG AGT GGG CCC CAT TAC AGT ATT TTG 
AAGY, were used as the 5' and 3' primers, respectively,  in the PCK 
reaction. The 5' and 3' primers contain 18 bases that are homolo- 
gous to the putative gene encoding the P.. vitcx Duffy antigen 
binding protein and the restriction sites for PvulI and ApaI, respec- 
tively. The product of the PCR reaction was restricted with PvulI 
and Apal,  electrophoresed on a 1% agarose gel, recovered using 
Geneclean II, and ligated with the vector. The ligation created a 
chimeric gene in which the HSV gD sequence was in frame with 
the malarial gene sequence. The method described above was used 
to make the constructs given below, except where stated otherwise. 
pHVDR22.  This construct contains DNA sequences  encoding 
region II (amino acids 198-522) of  the P. v/rex protein. The primers, 
5'TCT CGT CAG CTG ACG ATC TCT AGT GCT ATTY and 
5'ACG AGT GGG CCC TGT CAC AAC TTC CTG AGTY, and 
the phsmid p192B were used to amplify region II by PCK. 
pHVDR35.  This construct contains DNA sequences  encoding 
regions III-V (amino acids 516-922) of the P. vivax protein. The 
primers, 5'TCT CGT CAG CTG ACT CAG GAA GTT GTG 
ACAY and 5'ACG AGT GGG CCC TGC TTT GAC ATC TCT 
GTAY, and the plasmid p192B were used to amplify regions III-V 
by PCR. 
pHVDR66.  This construct contains DNA sequences  encoding 
region VI (amino acids 864-1000) of the gene encoding the P. vivax 
protein. The primers, 5'TCT CGT CAG CTG GAT GCA GAA 
GGA CAT GACY and 5'ACG AGT GGG CCC CGT AAA GCA 
CTT GTA GGA3  ~ and the plasmid p192B were used to amplify 
region VI by PCK. 
pHKBDR22.  This construct contains DNA sequences  encoding 
region II (amino acids 199-517) of the P. knowlesi B protein. The 
primers, 5'TCT CGT CAG CTG AGT GGT GTT ATT AAT 
CAAY and 5'ACG AGT GGG CCC CAA GTG TTC CTG AGT 
ATTY, and the plasmid pl0g which contains the P. knowlesi  B gene 
were used to amplify region II by PCK. 
pHKADR22.  This construct contains  DNA  sequences en- 
coding region II (amino acids 189-525) of the P. knowlesi o~ pro- 
tein. The P. knowlesi oL gene contains an internal EcoRI site and 
was cloned as two EcoRI fragments on the plasmids plcg and p6D. 
A DNA fragment encoding amino acids 189-276 of the P. knowlesi 
c~ protein was amplified by PCR using the primers 5'CTG CGT 
KTG AAT CGA AAG GAAY and 5'ACG AGT GGG CCC CAG 
GTC GAA TTC TTT GTT ATA TTG3  ~ and the plasmid Plcg, 
and was restricted with EcoKI. A DNA fragment encoding amino 
acids 276-525 of the P. knowlesi o~ protein was amplified by PCR 
using the primers 5'AGC ACG GAA TTC TGT AAG GAT ATA 
AGA TGGY and 5'ACG AGT GGG CCC TTC AAC ACC ACT 
TCC TACY, and the plasmid p6D, and was restricted with EcoKI 
and ApaI. A three-way ligation was performed with the two re- 
stticted PCK products and the vector. 
pHKGDR22.  This construct contains  DNA  sequences en- 
coding region II (amino acids 196-529) of the P. knowlesi ~/pro- 
tein. The P. knowlesi 'y gene contains an internal EcoKI site and 
was cloned as two EcoKI fragments on the phsmids plBg and p4.5. 
A DNA fragment encoding amino adds 196 to 399 of the P. knowlesi 
~/protein was amplified by PCK using the primers, 5'TCT CGT 
CAG CTG ATG TCT AGT GGT GCT ATTY and 5'ACG AGT 
GGG CCC CAG GTC GAA TTC TGA CAT ATA ATCY, and 
the plasmid plBg, and was restricted with PvulI and EcoKI. An- 
other DNA fragment  encoding  amino acids 399-529  of the P. 
knowlesi 'y protein was amplified by PCK using the primers 5'AGC 
ACG GAA TTC CGC GAA CAA CGA CGG AAAY and 5'ACG 
AGT GC~ CCC ACT GGG AGC CTT AGA TTCY, and the 
plasmid p4.5, and was restricted with ApaI and EcoKI. A three- 
way ligation was performed with the two restricted PCK products 
and the vector. 
Cell Culture and Transfection of C087  Cells 
COS7 cells (American Type Culture Collection [ATCC] CILL 
1651; Kockville, MD) were cultured in DMEM with 10% heat 
inactivated FCS (both from GIBCO BILL, Gaithersburg, MD) in 
a humidified COz (5%) incubator at 37~  Fresh monolayers of 
COS7 cells (30-50% confluent) in 3.5-cm diameter wells were trans- 
fected  with 5 #g of  plasmid DNA by the calcium phosphate precipi- 
tation method (13). Cells were grown on coverslips  for use in im- 
munofluorescence assays. The cells were washed three times with 
media 12-16 h after the transfection. The transfected cells were 
used for immunofluorescence  or erythrocyte binding assays 40-60 h 
after transfection. 
Iraraunofluorescence Assay for Expression  in COS7 Cells 
Transfected  COS7 cells were assayed  for expression  40-60 h after 
transfection. To check for expression of the chimeric proteins on 
the surface, the transfected COS7 cells were washed in PBS, fixed 
in 2% formaldehyde (in PBS) for 15 min at room temperature, 
washed in PBS, and stained with a primary antibody (1 h at room 
temperature) to amino acid sequences of HSV gD in the chimeric 
protein. Ascites fluid containing mAbs, ID3 or DL6 (provided by 
Drs. Gary Cohen and Koselyn Eisenberg; 11), which map to amino 
acids 11-19 and 272-279 of the mature HSV gD protein, respec- 
tively, were used as the primary antibodies (at a dilution of 1:2000 
in PBS containing 0.1% BSA). The cells were washed once in an 
excess of  PBS for 10 rain and incubated with fluorescein-conjugated 
goat anti-mouse antibodies (Jackson Immunogesearch  Laborato- 
ties, West Grove, PA) at a dihtion of 1:100 in PBS containing 0.1% 
BSA for 30 min. The cells were washed in an excess of PBS for 
10 min, mounted with Fhoromount (Southern Biotechnology As- 
sociates Inc., Birmingham, AL) and scored for surface expression 
using a fluorescence microscope. The mAbs, ID3 and DL6, were 
tested against untransfected COS7 cells to check for background 
fluorescence.  Sera  from an unimmunized mouse was used with trans- 
fected COS7 ceils as a negative control. A mouse mAb, HP13 
(provided by Dr. Charlotte Kaetzel, University of Kentucky, Lex- 
ington, KY; 14), raised against human protein disulfide isomerase 
(PDI), which is localized in the endoplasmic reticulum, was used 
as a control to ensure that fixing with formaldehyde did not per- 
meabilize the ceils. Ascites fluid containing mAb HP13 was used 
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meabilize the cells. Ascites fluid containing mAb HP13 was used 
as a primary antibody at a dilution of 1:500 in PISS  containing 0.1% 
BSA. The reactivity of HP13 against PDI in COS7 cells was tested 
by using it in the presence of 0.2% saponin, which permeabilizes 
the cells and allows access to PDI. To visualize the internal distri- 
bution of the chimeric proteins, the mAbs DL6 and 11)3 were also 
used in the presence of 0.2% saponin. Immunofluorescence assays 
for surface expression were also performed at 4~  (antibodies are 
not internalized by capping at this temperature) as described above 
but without fixing the cells. The cells were fixed in 2% formalde- 
hyde for 15 rain after staining with  the antibodies, just before 
mounting with Fhoromount. In this method, since the cells are 
not fixed before staining with antibodies,  there is no concern about 
permeabilization of the cells due to any fixing procedure. 
Erythrocytes and Pretreatments with Enzymes 
Blood was collected in 10% citrate phosphate dextrose (CPD) 
(Baxter, Deerfield, IL) and stored at 4~  for up to 4 wk. The Duffy 
phenotypes of the erythrocytes were determined by standard blood 
banking methods using two antisera (anti-Fya and anti-Fyb). Duffy- 
negative erythrocytes, Fy(a-b-),  did not  react with  either an- 
tiserum. The Duffy-positive erythrocytes used in the erythrocyte 
binding assays had the phenotype Fy(a+b+).  Erythrocytes were 
washed three times in RPMI 1640 (GIBCO BRL) and resuspended 
to a hematocrit of 10% in RPMI 1640 for use in the erythrocyte 
binding assay described below. Washed human and monkey erythro- 
cytes were treated with chymotrypsin, trypsin, and neuraminidase 
as described previously (15). 
Erythrocyte Binding Assay 
COS7 cells were transfected in 3.5-cm diameter wells and used 
for erythrocyte binding assays 40-60 h after transfection. 200 #1 
of a 10% erythrocyte suspension  was added to 2 ml of media in 
wells containing the transfected cells, the plate was swirled to mix 
the erythrocytes well, and the erythrocytes were allowed to settle 
over 2 h at 37~  The COS7 cells were then washed three times 
with 2 ml of PBS to remove nonadherent erythrocytes. Transfected 
COS7 cells with rosettes of adherent erythrocytes (see Fig. 4 for 
an example) were scored.  The number of rosettes was scored in 
either 10 or 20 fields at a magnification of 40 using an inverted 
microscope. Binding was scored as negative when no rosettes were 
seen in the entire well. 
The erythrocyte  binding assay  was followed by an immunoftuores- 
cence assay to ensure that COS7 cells with rosettes of adherent 
erythrocytes were transfected and expressed the chimeric proteins. 
After the erythrocyte binding assay, coverslips with COS7 cells and 
adherent erythrocytes were used in the immunofluorescence assay 
as described earlier. 
To study the effect of the chemokines MGSA and IL-8 on binding, 
the erythrocytes were resuspended to a hematocrit of 1% in 1 ml 
of complete DMEM and incubated for 1 h at room temperature 
with the chemokines at the required concentrations (stock solu- 
tions of purified MGSA and IL-8 at concentrations of 125 #M were 
provided by Dr. Richard Horuk, Genentech Inc., South San Fran- 
cisco, CA). The erythrocytes were then used in erythrocyte binding 
assays as described above. The number of COS7 cells with rosettes 
of adherent erythrocytes was scored in 20 randomly chosen fields 
at a magnification of 40 in each well and the percent inhibition 
was determined as follows: percent binding =  100 x  (no. of  bound 
COS7 cells in the presence of chemokines)/(no, of bound COS7 
cells in absence of chemokines); percent inhibition  =  100  -  per- 
cent binding; and percent inhibition  =  0 if binding (%) i> 100. 
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Results 
The System for Expressing Different Regions of the P.. vivax 
Protein to Study Erythrocyte Binding.  Different regions (I, II, 
I/I-V, and VI) of the P. t,  ivax protein were expressed on the 
surface of COS7 cells. The secretory signal sequence and trans- 
membrane segment ofHSV gD were used to target different 
regions of the malarial proteins to the COS7 cell surface. The 
HSVgD gene contains unique PvulI and ApaI sites, 27 amino 
acids downstream of the signal peptide cleavage site and 72 
amino adds upstream of the transmembrane segment, respec- 
tively (11, and Fig. 1). Different regions of the P. vivax gene 
were cloned between the PvulI and ApaI sites to create chi- 
meric genes. 
COS7 cells were transfected with these constructs which 
were designed to express regions I, II, III-V, and VI of the 
P. vivax protein. The transfected COS7 cells were fixed with 
formaldehyde and a pair of mAbs, DL6 and ID3,  to amino 
acid sequences of HSV gD flanking the cloning sites (11, and 
Fig.  1) were used to assay for surface expression of the chi- 
meric proteins by immunofluorescence microscopy. Fig.  2, 
A  and E  show the results of the immunofluorescence assays 
using the mAb DL6 with formaldehyde-fixed COS7 ceils that 
had been transfected with pHVDR22 and pHVDR35, respec- 
tively. The edges and protruding processes of these cells were 
stained indicating that the chimeric proteins were expressed 
on the cell surface. The mAbs DL6 and ID3 did not react 
with  untransfected COS7  cells. 
To ensure that the formaldehyde-fixing procedure did not 
permeabilize the COS7 cells, a mAb,  HP13,  raised against 
PDI, which is localized to the endoplasmic reticulum,  was 
used. HP13 did not react with formaldehyde-fixed COS7 cells 
(Fig.  2,  C  and G), indicating that  the cells have not been 
permeabilized and internal proteins are not accessible. When 
the formaldehyde-fixed COS7 cells were stained with HP13 
in the presence of saponin, which permeabilizes the cells, every 
cell was stained (Fig. 2, D and/-/). These experiments dearly 
showed that the formaldehyde-fixing procedure does not per- 
meabilize the cells and the staining of formaldehyde-fixed cells 
with DL6 and ID3 indicates that the chimeric proteins are 
expressed on the surface of the COS7 cells. The internal dis- 
ID3  DL6 
HSV gD  malaria  gene  HSV gD 
Figure  1.  Chimeric constructs ofHSV glycoprotein D (HSVgD) and 
malaria sequences for the expression of different regions of the P. vivax 
and P. knowlesi  erythrocyte binding proteins on the COS7 cell surface. 
HSV gD has a signal sequence (ss) of 25 amino acids at the NH2-terminal 
end and a 24 amino acid hydrophobic transmembrane segment (tin) with 
a 30 amino acid cytoplasmic tail (cyt) at the COOH-terminal  end (12). 
HSV gD has a unique PvulI restriction site 27 amino acids downstream 
of the signal peptide cleavage site and a unique ApaI restriction site 71 
amino acids upstream of the transmembrane segment (12). HSV gD has 
a proline-rich region (ppp) adjacent to the transmembrane segment. The 
mAb ID3 reacts with amino acids 11-19, and the mAb DL6 reacts with 
amino acids 272-279 of the mature HSV gD protein (11). Figure  2.  Immunoftuorescence  assays showing surface expression of chimeric proteins containing regions of the P. vivax protein in transfected COS7 
cells. Immunofluorescence  assays on COS7 cells transfected with pHVDR22 (A-D) and pHVDR35 (E-H), which contain region II and regions III-V 
of the P. vivax protein, respectively. The mAb DL6, which reacts against amino acid sequences of HSV gD in the chimeric proteins, was used with 
formaldehyde-fixed ceils in the absence (A and E) or presence (B and F) of saponin, which permeabilizes the cells. The mAb HP13, which reacts against 
human PDI, was used in the absence (C and G) or presence (]9 and/4) of saponin  to test if the formaldehyde-fixing  procedure permeabilizes  COS7 
cells. HP13 stained formaldehyde-fixed ceUs only in the presence of saponin,  indicating that formaldehyde  fixing did not permeabilize the ceils. Note 
the immunofluorescence  patterns with DL6 in the absence (surface pattern, A  and E) or presence (internal pattern, B and F) of saponin.  Bar, 75/~M. 
tribution of the chimeric proteins is seen when the trans- 
fected cells are stained with DL6 in the presence of saponin 
(Fig. 2, B and F). COS7 cells transfected with each construct 
shown in Fig. 3 gave immunoftuorescence patterns with the 
mAbs DL6 and HP13, that were similar to those shown in 
Fig. 2, indicating that each chimeric protein tested was tar- 
geted to the cell surface. The transfection efficiency (the per- 
centage of COS7 cells with surface immunofluorescence)  varied 
from *0.5 to 10% depending on the construct and transfec- 
tion conditions. 
Expression of the chimeric proteins on the surface of trans- 
fected COS7 cells was also tested by a different immunofluores- 
cence assay. In this assay, the transfected COS7  cells were 
stained with the primary and secondary antibodies at 4~ 
before fixing with formaldehyde. The results of this assay 
with the mAbs DL6 and HP13 were identical to those de- 
scribed with formaldehyde-fixed cells, in that, DL6 stained 
transfected cells in the absence of saponin, and HP13 stained 
cells only in the presence of saponin. The results from these 
assays indicate that all the chimeric proteins were targeted 
to the surface of COS7 cells. 
Region II of the P. vivax Protein Is  the Erythrocyte Binding 
Domain.  COS7  cells  transfected with constructs that ex- 
pressed the different regions of the P. vivax protein were tested 
for their ability to bind Duffy-positive and -negative human 
erythrocytes. The transfection efficiency for each construct 
was determined by the immunofluorescence assay described 
above. The transfection efficiency and the number of COS7 
cells with rosettes of adherent erythrocytes seen in 20 fields 
at a magnification of 40 is shown in Table 1 for each con- 
struct in three separate experiments.  In cases where the binding 
of erythrocytes is reported as negative, no rosettes were seen 
in the entire well.  COS7 cells expressing region II of the 
P.  vivax  protein bound  Duffy-positive, but  not  -negative, 
human erythrocytes (Fig.  3,  and Fig.  4, A  and B).  When 
the  erythrocyte binding  assay  was  followed  by  an  im- 
munoftuorescence assay on the same cells, it was found that 
whereas all  COS7 cells with rosettes of adherent erythro- 
cytes were transfected and expressed region II,  not all the 
COS7 cells that expressed region II bound erythrocytes. This 
is probably due to different levels of expression in these calls. 
No rosettes of either Duffy-positive or -negative erythrocytes 
were seen in wells containing COS7 ceils expressing regions 
I, Ill-V, and VI of the P. vivax protein (Fig.  3,  and Fig.  4, 
pHVDRll 
pHVDR22 
pHVDR35 
pHVDR66 
I 
I  I 
11  III  -  V  Vl  BLNDING TO ERYTHROCYTES 
I  I  I  DUFFY  POS.  DUFFY  NEG. 
5's  3'CYS 
Figure  3.  Identification of region II of the P. vit,  ax pro- 
tein as an erythrocyte binding domain. The extracellular do- 
main of the P. vi~  protein was divided into six regions as 
described previously (8).  COS7 cells were transfected  with 
the plasmids shown and expressed different regions (regions 
I, II, Ill-V, and VI, each indicated by a line) of the P. vivax 
protein on the COS7 cell surface. The transfected cells were 
tested  for their ability to bind Duffy-positive or -negative 
human erythrocytes. (+) Rosettes of adherent erythrocytes 
were seen on the COS7 cells. (-) No rosettes were seen. 
500  Duffy Binding Proteins of Malaria Table  1.  Binding of Duffy-positive and -negative Human 
Erythrocytes to Regions of the P. vivax Protein 
Binding  of  Binding  of 
Region of  Duffy-positive  Duff-y-negative 
P. vivax  Transfection  human  human 
protein*  ef~ciencyt  erythrocytesS  erythrocytesS 
% 
I  0.5  - 
3.0 
2.5 
II  2.1  225 
3.0  238 
5.1  18011 
IlI-V  5.0  - 
1.3 
1.0 
VI  1.0  - 
2.5 
2.5 
m 
m 
* COS7 cells were transfected with constructs designed to express chi- 
meric proteins  containing different regions of the P. vivax protein and 
the signal sequence and transmembrane  segment of HSV gD. 
* The transfection efficiency was determined by an immunofluorescence 
assay  using the mAb DL6,  which recognizes amino acid sequences of 
HSV gD in the chimeric proteins.  Results from three independent  ex- 
periments  are shown  for each construct. 
S The number of COS7 cells with rosettes of adherent erythrocytes seen 
in 20 fields at a magnification of 40. Minus signs ( -  ) indicate no rosettes 
were seen in the entire walt. Results from three independent experiments 
are shown  for each construct. 
The number of COS7 cells with rosettes of adherent erythrocytes seen 
in  10 fields  at  a magnification  of 40. 
C  and D).  These experiments identified region II,  the 5' 
cysteine-rich region of the P. vivax protein, as an erythrocyte 
binding domain. 
It has been shown previously that a  140-kD  protein in 
P. v/rex culture supernatants binds Duffy-positive but not -neg- 
ative human erythrocytes (5).  The binding of region II of 
the R  vivax protein to enzyme-treated human erythrocytes 
and rhesus erythrocytes paralleled the known binding profile 
of the 140-kD protein (Table 2).  Chymotrypsin treatment 
of Duffy-positive human erythrocytes destroys the Duffy blood 
group antigen and these enzyme-treated erythrocytes did not 
bind region II of the R vivax protein (Table 2). Trypsin treat- 
ment, which does not cleave the Duffy blood group antigen, 
or neuraminidase treatment, which removes only sialic acid 
residues, did not affect the binding ofR vitcx region II (Table 
2). Rhesus erythrocytes, which are Duffy positive, did not 
bind P. vivax region II, indicating that the R  vivax binding 
domain specifically binds the human Duffy blood group an- 
tigen. The correlation of the binding profiles indicates that 
the binding of region II to human erythrocytes was specific 
and that the cloned R vivax gene indeed encodes the 140-kD 
R  vivax Duffy antigen binding protein. The binding of re- 
gion II and the 140-kD protein to the erythrocytes described 
correlates with  their  susceptibility to invasion by R  vivax 
(Table 2). 
Erythrocyte Binding Specificities of  Region II of  the P. knowlesi 
or, ~, and ~  Proteins.  The simian malaria, R  knowlesi, in- 
vades both Duffy-positive human erythrocytes and erythro- 
cytes from rhesus monkeys, the host in which this parasite 
is maintained in the laboratory. R  knowlesi has three genes 
(c~, 3, and 3,) that are homologous to the single copy gene 
that encodes the P. vivax Duffy antigen binding protein (8). 
COS7 cells expressing region II of the P. knowlesi ol, 3, and 
3' proteins were tested for binding to erythrocytes. Whereas 
region II of all three P. knowlesi proteins (ol, 3, and 3') bound 
rhesus erythrocytes, region II of only the ol protein bound 
Table  2.  Comtmriso. of Erythrocyte Invasion by P. vivax to the Binding of P. vivax Region II and the Binding of the 140-kD 
P. vivax Protein to these Erythrocytes 
P.  vivax 
Enzyme  P. vivax  region II  P. vivax 
Erythrocytes  treatment  140-kD binding*  binding*  invasion s 
Human Duffy positive  None  +  +  + 
Human Duffy negative  None  -  -  - 
Human Duffy positive  Chymotrypsin  -  -  - 
Human Duffy positive  Trypsin  +  +  + 
Human Duffy positive  Neuraminidase  +  +  + 
tLhesus  None  -  -  - 
Mouse  None  -  -  - 
* Binding of the 140-kD Duffy antigen binding protein  from P. vivax culture supematants  to erythrocytes.  ( + ) Binding;  ( -  )  no binding.  Data 
from Wertheimer  and Barnwell  (5). 
Binding of erythrocytes  to COS7 cells expressing region II of the P. vivax protein.  ( + ) Binding;  ( -  )  no binding. 
S Invasion of erythrocytes  by P.  vivax from Barnwell  et al.  (29).  ( + )  Erythrocytes  invaded;  ( -  )  erythrocytes  not  invaded. 
501  Chitnis and Miller Figure 4.  Erythrocyte binding assay. Erythrocyte binding assays with transfeeted COS7 cells expressing either P. vivax region 1I (A and B) or ex- 
pressing P. vivax regions III-V (C and D).  Duff-y-positive (-4 and C) or -negative (B and D) human erythrocytes were used in the assay. Note the 
two cells in A  covered with Duffy-positive human erythrocytes.  Bar, 50/xM. 
Table  3.  Comparison  of Erythrocyte  Invasion  by P.  knowlesi  to  the Binding  of Region  II of the P.  knowlesi or, ~,  and 9/Proteins 
and the  Binding  of the  135-kD  P.  knowlesi  Protein  to  these Erythrocytes 
P.  knowlesi  ot  P.  knowlesi  3  P.  knowlesi  "y 
Enzyme  P.  knowlesi  region II  region II  region II  P.  knowlesi 
Erythrocytes  treatment  135-kD binding"  binding*  binding*  binding*  invasions 
Rhesus  None  +  56  >100  >100  + 
Human Duffy positive  None  +  20  -  -  + 
Human Duffy negative  None  ..... 
Human Duffy positive  Chymotrypsin  ..... 
Rhesus  Chymotrypsin  -  -  >100  >100  + 
Mouse  None  ..... 
" Binding of the 135-kD Duffy antigen binding protein  from P. knotvlesi culture  supernatants to erythrocytes from Haynes et al. (6). (+) Binding; 
(-) no binding. 
* Binding of erythrocytes to COS7 cells expressing region II of the P. knowlesi or, fl, or 3' protein. The number of COS7 cells with rosettes of adher- 
ent erythrocytes seen in 10 fields (~) or 5 fields (fl, 3') at a magnification of 40 is shown.  The transfection efflciencies for the or,  B, and 3' genes 
were 4,  1.9, and 5.5%  respectively. (-) No rosettes were  seen in the entire well. Three independent experiments  gave similar results. 
s Invasion of erythrocytes by P. knowlesi from  Haynes et  al.  (6). (+) Erythrocytes invaded; (-) erythrocytes not invaded. 
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3). The binding profile of region II of the oe protein paral- 
leled the known binding profile of the 135-kD P. knowlesi 
protein (Table 3), indicating that the ot gene encodes the 135- 
kD P. knowlesi Duffy antigen binding protein,  the parasite 
ligand that mediates erythrocyte invasion by the Duffy an- 
tigen-dependent pathway. 
The binding domains (region II) of the P. knowlesi (3 and 
3' proteins have different binding specificities compared with 
the oL protein. Region II of the [3 and '7 proteins bound rhesus 
erythrocytes but not human erythrocytes (Table 3). In addi- 
tion, region II of the [3 and 3' proteins bound chymotrypsin- 
treated rhesus erythrocytes (Table 3). As chymotrypsin de- 
stroys the Duffy blood group antigen on rhesus erythrocytes, 
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Figure 5.  Inhibition by chemokines  (MGSA and Ib8) of erythrocyte 
binding to region  II of the R knowlesi  ~ and R vivax proteins.  Duffy-positive 
human erythrocytes  were preincubated  with different concentrations  of 
MGSA (,4) or I1.,8 (B) and were used in binding assays with transfected 
COS7 cells that expressed  region II of the P. know/e~  o~ (O---O) or R vivax 
(O- ￿9 -0) proteins on their surface. The inhibition of erythrocyte  inva- 
sion by R knowlesi ([-1-[]) with MGSA (,4) or Ib8 (B) is adapted from 
Horuk et al. (3). 
the attachment of these erythrocytes to region II of the B 
and 3" proteins indicates that the Duffy blood group antigen 
is not the receptor for these ligands. The P. knowlesi ligands 
encoded  by  the  [3  and  3'  genes  bind  as  yet  undefined 
chymotrypsin-resistant receptors on rhesus erythrocytes. 
MGSA and IL-8 Block  the Binding of Duffy-positive Human 
Erythrocytes to Region  II of the P. vivax and P. knowlesi Duffy 
Antigen Binding Proteins.  We have shown recently that the 
Duffy blood  group  antigen  is  a  receptor  for  a  family of 
chemotactic  and  proinflammatory  peptides  that  includes 
MGSA and IL-8 (3). The chemokines, MGSA and IL-8, block 
the binding of the 135-kD P. knowlesi Duffy antigen binding 
ligand to Duffy-positive human erythrocytes and inhibit the 
invasion of these erythrocytes by P. knowlesi (3). It is difficult 
to do similar studies with P. vivax because of technical prob- 
lems in culturing P. vivax. The method developed here allows 
direct studies on the inhibition of this receptor-ligand inter- 
action of P. vivax. Duffy-positive human erythrocytes were 
preincubated with the chemokines, MGSA and IL-8, and used 
in erythrocyte binding assays. MGSA and IL-8 blocked the 
binding of Duffy-positive human erythrocytes to COS7 cells 
expressing region II of the P. vivax and P. knowlesi Duffy an- 
tigen binding proteins on their surface (Fig. 5). The number 
of COS7 cells with rosettes of bound erythrocytes was deter- 
mined in 20 randomly chosen fields at a magnification of 40 
for  each  well.  In  one  experiment,  in  the  absence  of any 
chemokines, 75 and  102 rosettes of Duffy-positive human 
erythrocytes were seen with COS7 cells expressing regions 
II of the P. vivax and P. knowlesi Duffy antigen binding pro- 
teins, respectively. These values were used to determine the 
percent inhibition of binding in the presence of the chemokines 
(Fig. 5). Data on the inhibition of erythrocyte invasion by 
MGSA and IL-8 was reported previously (3) and are shown 
in Fig. 5 for comparison. MGSA inhibited erythrocyte binding 
more efficiently than IL-8. An approximately 10-fold higher 
concentration of IL-8 than MGSA was required to achieve 
50%  inhibition of erythrocyte binding to region II of the 
P. vivax and P. knowlesi proteins (Fig. 5). This difference be- 
tween MGSA and IL-8 is similar to that reported previously 
for the inhibition of erythrocyte invasion by P. lenowlesi (Fig. 5). 
Discussion 
The invasion of erythrocytes by malarial merozoites is a 
multi-step process that involves several molecular interactions. 
The early steps of erythrocyte invasion include: (a) initial at- 
tachment, (b) apical reorientation,  and (c) junction forma- 
tion that initiates entry into the vacuole (16).  P. vivax  and 
R  knowlesi require the Duffy blood group antigen for inva- 
sion of human erythrocytes. When P. knowlesi merozoites in- 
teract with Duffy-negative human erythrocytes that lack the 
Duffy blood group antigen, initial attachment and apical re- 
orientation take place normally but a junction between the 
invading merozoite and target erythrocyte does not form and 
invasion is aborted (4). These studies showed that the forma- 
tion of a junction is necessary for erythrocyte invasion and 
P. knowlesi uses the Duffy blood group antigen as a receptor 
for junction formation.  It is not possible to do similar ex- 
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in isolating invasive  P. vivax merozoites. However, by analogy, 
it appears likely that P. vivax also uses the Duffy blood group 
antigen as a receptor for junction formation during invasion. 
Previous studies have identified a 135-kD P. knowlesi pro- 
tein and a 140-kD P. vivax protein that bind Duffy-positive 
but not -negative human erythrocytes  (5, 6). These studies 
used an erythrocyte binding assay in which the erythrocytes 
were first incubated with metabolically labeled parasite cul- 
ture supematants. The erythrocytes with bound parasite pro- 
teins were then centrifuged through oil. The bound parasite 
proteins were eluted with salt, separated by gel electropho- 
resis, and visualized by autoradiography.  This erythrocyte 
binding assay is limited in that it only detects those parasite 
proteins that are released into culture supernatants in a form 
capable of binding erythrocytes. For example, P. knowlesi pro- 
teins from culture supernatants did not bind chymotrypsin- 
treated rhesus erythrocytes, even  though these treated erythro- 
cytes are invaded normally (6). In addition, the molecular 
characterization  of the binding domains of the erythrocyte 
binding proteins identified was not possible with this assay. 
Region II of the P. vivax and P.. knowlesi Proteins Is the Eryth- 
rocyte Binding Domain.  The cloning of the putative  genes 
encoding the erythrocyte binding proteins  of P. vivax  and 
P. knowlesi enabled us to take a molecular approach to study 
their interactions with erythrocytes. In this study, we identified 
region II of these proteins as an erythrocyte binding domain 
and studied the binding specificity of this domain. Region 
II of the P.  vivax  protein bound Duff-y-positive, but  not 
-negative, human erythrocytes.  In addition, the binding of 
P. vivax region II to normal and enzyme-treated human and 
rhesus erythrocytes paralleled the known binding profile of 
the 140-kD P. vivax  Duffy antigen binding protein (Table 
2). The binding of region II to erythrocytes  also correlated 
with the susceptibility of these erythrocytes to invasion by 
P. vivax. P. uivax invades aU erythrocytes  that bound to re- 
gion II of the P. vivax protein and does not invade erythro- 
cytes from rhesus monkeys and mice which did not bind to 
region II of the P. vivax protein (Table 2). 
We have demonstrated that when expressed in the COS7 
cell expression system developed here, region II of the P. vivax 
protein binds erythrocytes. Moreover, we have demonstrated 
that region II of the P. vivax protein binds erythrocytes with 
the same specificity as the parasite protein it is derived from. 
The perfect correlation between binding of region II and the 
140-kD P. vivax protein identified region II as a binding do- 
main. None of the other regions bind erythrocytes when ex- 
pressed in COS7 cells using this system. However, we cannot 
rule out a role for these regions in erythrocyte binding based 
on these data. 
Region II of the P. knowlesi o~,/3, and 3' proteins also con- 
rains erythrocyte binding domains, but these proteins have 
different binding specificities. Region II of all three P. knowlesi 
proteins  (a,  /3,  and 3')  bound erythrocytes  from rhesus 
monkeys, the laboratory host for P. knowlesi (Table 3). In ad- 
dition, region II of the P. knowlesi c~ protein also bound Duffy- 
positive human erythrocytes which are invaded by P. knowlesi 
(Table 3). The binding profile of region II of the P. knowlesi 
c~ protein paralleled the known binding profile of the 135- 
kD P. knowlesi protein (Table 3), indicating that the c~ gene 
encodes the 135-kD Duffy antigen binding protein, the parasite 
ligand that mediates erythrocyte invasion by the Duffy an- 
tigen-dependent pathway. 
The genes for the P. vivax and P. knowlesi proteins bdong 
to a gene family encoding erythrocyte binding proteins that 
also includes the P. fakiparum sialic acid binding protein (8). 
These genes have similar structures and share regions of amino 
acid homology, suggesting a common evolutionary origin 
(8). [Legion II, the binding domain of the P. vivax  and P. 
knowlesi erythrocyte binding proteins, is one of the two regions 
of these proteins that contains conserved cysteines and aro- 
matic amino acid residues (8). The cysteines probably form 
structurally  important disulfide bonds and the hydrophobic 
residues may play a role in the folding of the binding domain 
through hydrophobic interactions.  Conservation of the cys- 
teines and hydrophobic amino acid residues in region II sug- 
gests that  the binding domains  of these proteins  share a 
common structural motif that is used for erythrocyte binding. 
A computer search of the protein and nucleic acid data bases 
using the BLAST algorithm (17) revealed that these erythro- 
cyte binding proteins are not homologous to any other known 
proteins. The spacing of the conserved cysteines and aromatic 
residues in region II may define a unique structural motif 
that is used for erythrocyte binding. The differences in the 
amino acid sequences found in region II of the P.  knowlesi 
and  P.  vivax  proteins  probably  confer  different  binding 
specificities to these proteins.  The binding domains of the 
P. vivax  and P.  knowlesi erythrocyte binding proteins  lie in 
a region of homology with the sialic acid binding protein 
of P. fakiparum.  The approach described here has been used 
to demonstrate that the domain responsible  for  the sialic 
acid-dependent binding of the P. fakiparum protein also lies 
in the homologous cysteine-rich region (region II) (18). Se- 
quence analysis of rKNA genes has demonstrated that the 
primate malarias P. vivax  and P. knowlesi are evolutionarily 
distant  from P. fakiparum  which is more closely related to 
the avian malarias (19). Conservation of functional domains 
in evolutionarily distant malaria species was also seen in the 
case of the circurnsporozoite protein where the only conserved 
regions (regions I and II) between P. knowlesi and P.fakiparum 
were shown to bind hepatocytes (20, 21). A recent study (22) 
used soluble recombinant polypeptides from different regions 
of the P. fakiparum sialic acid binding protein in erythrocyte 
binding assays and found that a polypeptide spanning amino 
acids 869-982,  which lie outside region II, bound erythro- 
cytes in a sialic acid-independent manner. Whether the binding 
of this polypeptide to erythrocytes plays a role in erythrocyte 
invasion, however, remains  to be demonstrated. 
Multiple Erythrocyte Binding Ligands Provide Redundancy in 
Erythrocyte Invasion Pathways.  The binding domains (region 
lI) of the P. knowlesi/3 and 3` proteins have different binding 
specificities compared to the P. knowlesi a  protein. Region 
II of the 13 and 3' genes bound rhesus erythrocytes but did 
not bind either Duff'y-positive or -negative human erythro- 
cytes (Table 3). In addition, region II of the/3 and 3' genes 
bound chymotrypsin-treated rhesus erythrocytes which have 
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is known to invade normal and chymotrypsin-treated rhesus 
erythrocytes at the same rate, indicating that P. knowlesi has 
alternate pathways for the invasion of rhesus erythrocytes that 
do not depend on the Duffy blood group antigen (6). The 
ligands encoded by the P. knowlesi [3 and 3' genes may mediate 
junction formation with chymotrypsin-treated  rhesus erythro- 
cytes allowing the invasion of these erythrocytes by Duffy 
antigen-independent pathways. Although these ligands evi- 
dently do not occur in culture supernatants in a form that 
binds chymotrypsin-treated rhesus erythrocytes, the mRNAs 
for these proteins are expressed as measured by reverse tran- 
scription with gene-spedfic primers (8). P. knowlesi can also 
invade trypsin-treated human Duffy-negative erythrocytes (6). 
Trypsin treatment may uncover receptors on the erythrocyte 
surface that are used for invasion by P. knowlesi. Parasite ligands 
that bind these receptors have also not yet been found. Re- 
gion II of the P. knowlesi or, [3, and 3' genes did not bind 
these erythrocytes. Although the possibility that other regions 
of the P. knowlesi or, [3, and 3' genes may contain the binding 
domain for the trypsin-treated Duffy-negative human erythro- 
cytes cannot be ruled out, it appears likely that P. knowlesi 
uses an as yet undefined ligand to invade these treated Duff-y- 
negative erythrocytes by a pathway that is independent of 
the Duffy blood group antigen. 
This apparent redundancy in invasion pathways for P. know- 
lesi may be an important survival strategy. The lack of such 
redundancy in P. vivax may explain  the absence of P. vivax 
from West Africa where almost 95% of the people have the 
Duffy-negative phenotype and are resistant to P. vivax. Inva- 
sion by alternate pathways has also been described for P. jal- 
ciparum (23-25).  For example,  the P. fakiparum clone Dd2 
uses sialic acid residues on glycophorins for invasion, but can 
switch its phenotype to invade erythrocytes by a sialic acid-in- 
dependent pathway at a frequency of 10 -4 (Dolan, S. A. and 
L. H. MiUer, unpublished data).  When these rare parasites 
were selected by continuous culture in neuraminidase-treated 
erythrocytes, the selected parasite  line could invade  neur- 
aminidase-treated erythrocytes at the same efl~dency  as normal 
erythrocytes (26). The redundancy in invasion pathways may 
permit parasite survival in case of mutations in host receptors. 
For example, although deletion of glycophorin A or B occurs 
in various parts of Africa (27, 28), P. fakiparum has not been 
eliminated, presumably because of its ability to invade by al- 
ternate pathways. 
Applications of the New Erythrocyte Binding Assay.  It has 
been shown previously that the Duffy blood group antigen 
is the erythrocyte chemokine receptor (3). The chemokines, 
IL-8, and MGSA, block the binding of the 135-kD P. knowlesi 
Duffy antigen binding ligand and block invasion of Duffy- 
positive human erythrocytes (3). It is difficult to do the same 
studies with P. vivax because of technical problems in cul- 
turing P. vivax.  The method developed here allows direct 
studies on the inhibition of this receptor-ligand interaction 
of P. vivax.  MGSA and IL-8 blocked the binding of Duffy- 
positive human erythrocytes to COS7 ceils expressing region 
II of the P. vivax and P. knowlesi Duffy antigen binding pro- 
teins on their surface. This method can now be used to study 
the P. vivax receptor-ligand interaction at the molecular level 
and  develop  chemokine analogues  for  receptor-blockade 
therapy. If antibodies to the binding domain are effective at 
blocking the receptor-ligand interaction, it may also be pos- 
sible to use the binding domains as a vaccine against malaria. 
The efficacy  of antibodies to such an immunogen in blocking 
the receptor-ligand interaction can be followed with the in 
vitro erythrocyte binding assay. 
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